ARUNA SUBRAMANIAN TRIAL

To earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant Physicians should claim only the credit commensurate with the extent of their participation in the activity. Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. To provide continuing education for the healthcare team. In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing MedicalĮducation (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. Secondary transmission of coronavirus disease from presymptomatic persons, China. Effective treatment of severe COVID-19 patients with tocilizumab. Warren T, Jordan R, Lo M, et al.Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. COVID-19, SARS and MERS: are they closely related?. Petrosillo N, Viceconte G, Ergonul O, et al.Coronavirus map: tracking the global outbreak. Race to find COVID-19 treatment accelerates. Early safety indicators of covid-19 convalescent plasma in 5,000 patients. Joyner M, Wright RS, Fairweather D, et al.COVID-19 Dashboard by the Center for Systems Science and Engineering. Of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment Compassionate use of remdesivir for patients with severe covid-19. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Gordon DE, Jang GM, Bouhaddou M, et al.Remdesivir for 5 or 10 days in patients with severe covid-19. Observational study of hydroxychloroquine in hospitalized patients with covid-19. SARS and MERS: recent insights into emerging coronaviruses. de Wit E, van Doremalen N, Falzarano D, et al.Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnershipįor unprecedented times. Respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute Cavalli G, De Luca G, Campochiaro C, et al.Features, Evaluation and Treatment Coronavirus (COVID-19).

ARUNA SUBRAMANIAN TRIAL

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19.

Boulware DR, Pullen MF, Bangdiwala AS, et al.Deployment of convalescent plasma for the prevention and treatment of COVID-19. Bloch EM, Shoham S, Casadevall A, et al.Remdesivir for the treatment of covid-19 - preliminary report. Beigel JH, Tomashek KM, Dodd LE, et al.

Aruna subramanian